Metolar 3D 25 Tablet ER is a combination antihypertensive medication containing Chlorthalidone 12.5 mg, Metoprolol Succinate 25 mg, and Telmisartan 40 mg. This extended-release formulation is designed to provide sustained blood pressure control in patients with hypertension. Chlorthalidone, a thiazide-like diuretic, promotes the excretion of sodium and water, reducing blood volume and peripheral vascular resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing myocardial oxygen demand. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and decreased blood pressure. The combination of these three agents offers complementary mechanisms to achieve effective antihypertensive action, improve cardiovascular outcomes, and reduce the risk of stroke, myocardial infarction, and heart failure. Metolar 3D 25 Tablet ER is indicated for the management of essential hypertension, especially in patients who require multiple drug therapy. It should be used under medical supervision with regular monitoring of blood pressure, renal function, and electrolytes to minimize potential adverse effects such as hypotension, electrolyte imbalance, bradycardia, and renal impairment.